appears to have value in this space, as does KIM-1.
3] Nonstandard abbreviations: HF, heart failure; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal proBNP; MR-proANP, midregional proatrial natriuretic peptide; IL, interleukin; ST2L, membrane-bound ST2; sST2, soluble ST2; GDF-15, growth differentiation factor 15; CRP, C-reactive protein; TNF-[alpha], tumor necrosis factor a; PTX3, pentraxin 3; MPO, myeloperoxidase; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases; Gal-3, galectin-3; ET-1, endothelin-1; UCN-1, urocortin-1; AVP, arginine vasopressin; ADM, adrenomedullin; MR-proADM, midregional pro-ADM; RDW, red blood cell distribution width; eGFR, estimated glomerular filtration rate; NGAL
, neutrophil gelatinase-associated lipocalin.
The urine biomarkers NGAL
and KIM-1 can detect potential drug-induced damage to kidney cells in human clinical trials at a much earlier stage of renal toxicity than the nonspecific BUN (Blood Urea Nitrogen) and serum creatinine markers traditionally used to detect kidney damage.
6] Nonstandard abbreviations: T2DM, type 2 diabetes mellitus; IL, interleukin; TNF[alpha], tumor necrosis factor a; NGAL
, neutrophil gelatinase--associated lipocalin; BMI, body mass index; PBS, phosphate-buffered saline; CRP; C-reactive protein; RBP4, retinol binding protein 4; HOMA-IR, homeostasis model assessment index for insulin resistance; hs-CRP; high-sensitivity C-reactive protein; A-FABP, adipocyte-fatty acid binding protein 4.
With the help of a new diagnostic test that can aid in detecting NGAL
, physicians can significantly reduce the risk of AKI by using simple measures such as hydration or blood pressure support to lower the risk of harm," said Sudarshan Hebbar, M.
In this study of 301 critically ill patients, plasma NGAL
measured with the Triage NGAL
Test was a statistically significant diagnostic marker for AKI development within the next 48 hours (area-under-ROC 0.
In a scientific poster presented at AACC today by researchers at the University of Toronto, eleven heart transplant patients were treated with anti-rejection drug combinations and monitored with the Urine NGAL
assay within twelve hours of administration.
Data Presented at American Association for Clinical Chemistry (AACC) Meeting Show Urine NGAL
Can Potentially Save Lives by Enabling Faster Detection of Acute Kidney Injury
Biosite also confirmed that the training study for its Triage NGAL
Test was launched in the first quarter of 2007.
Commenting on its kidney injury program, Biosite reported that it intends to perform additional investigational studies, beginning in the first quarter of 2007, prior to starting the KINGPIN (Kidney Injury Assessment Using NGAL
in Cardiopulmonary Bypass Patients) validation trial.
is a biomarker that has been reported to be valuable in assisting physicians in rapidly and accurately diagnosing acute kidney failure in a matter of hours compared to current tests that may take up to several days.
Under the collaboration, Biosite will make antibodies to NGAL
using its proprietary antibody development process, which combines immunization of mice and phage display technology to generate highly diverse libraries of Omniclonal(R) antibodies with high affinity and low cross-reactivity.